{"doi":"10.1111\/j.1365-2125.2005.02360.x","coreId":"136047","oai":"oai:bradscholars.brad.ac.uk:10454\/3430","identifiers":["oai:bradscholars.brad.ac.uk:10454\/3430","10.1111\/j.1365-2125.2005.02360.x"],"title":"Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers","authors":["Al-Amoud, A.L.","Clark, Brian J.","Assi, Khaled H.","Chrystyn, H."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2005","abstract":"NoAims\\ud\nTo determine the bioavailability of gentamicin to the lung following inhalation from two jet nebulizers.\\ud\n\\ud\n  \\ud\nMethods\\ud\nSerial urine samples were obtained from 10 volunteers after a 80 mg dose given orally, nebulized from a Pari LC + (PARI) and MicroNeb III (MN) devices, or after a 40 mg intravenous dose. In vitro aerodynamic characteristics of the nebulized doses were also determined.\\ud\n\\ud\n  \\ud\nResults\\ud\nThe mean (SD) absolute gentamicin lung bioavailalibility following delivery by PARI and MN devices was 1.4 (0.4) and 1.7 (0.5) %. The mass median aerodynamic diameter (MMAD) of the drug particles from the PARI and MN systems was 8.6 (0.6) and 6.7 (0.5) \u00b5m and the corresponding fine particle doses (FPD) were 10.2 (2.8) and 11.7 (1.5) mg.\\ud\n\\ud\n  \\ud\nConclusions\\ud\nThe MMAD and FPD data reflect the poor lung deposition of gentamicin identified by urinary excretion","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":null,"rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/3430<\/identifier><datestamp>\n                2016-08-18T17:14:51Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nDetermination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers<\/dc:title><dc:creator>\nAl-Amoud, A.L.<\/dc:creator><dc:creator>\nClark, Brian J.<\/dc:creator><dc:creator>\nAssi, Khaled H.<\/dc:creator><dc:creator>\nChrystyn, H.<\/dc:creator><dc:subject>\nBioavailability<\/dc:subject><dc:subject>\nGentamicin<\/dc:subject><dc:subject>\nInhalation<\/dc:subject><dc:subject>\nLungs<\/dc:subject><dc:subject>\nNebulizer<\/dc:subject><dc:description>\nNo<\/dc:description><dc:description>\nAims\\ud\nTo determine the bioavailability of gentamicin to the lung following inhalation from two jet nebulizers.\\ud\n\\ud\n  \\ud\nMethods\\ud\nSerial urine samples were obtained from 10 volunteers after a 80 mg dose given orally, nebulized from a Pari LC + (PARI) and MicroNeb III (MN) devices, or after a 40 mg intravenous dose. In vitro aerodynamic characteristics of the nebulized doses were also determined.\\ud\n\\ud\n  \\ud\nResults\\ud\nThe mean (SD) absolute gentamicin lung bioavailalibility following delivery by PARI and MN devices was 1.4 (0.4) and 1.7 (0.5) %. The mass median aerodynamic diameter (MMAD) of the drug particles from the PARI and MN systems was 8.6 (0.6) and 6.7 (0.5) \u00b5m and the corresponding fine particle doses (FPD) were 10.2 (2.8) and 11.7 (1.5) mg.\\ud\n\\ud\n  \\ud\nConclusions\\ud\nThe MMAD and FPD data reflect the poor lung deposition of gentamicin identified by urinary excretion.<\/dc:description><dc:date>\n2009-09-14T07:01:15Z<\/dc:date><dc:date>\n2009-09-14T07:01:15Z<\/dc:date><dc:date>\n2005<\/dc:date><dc:type>\nArticle<\/dc:type><dc:type>\nNo full-text available in the repository<\/dc:type><dc:identifier>\nAl-Amoud, A.L., Clark, B.J., Assi, K.H. and Chrystyn, H. (2005).  Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers.   British Journal of Clinical Pharmacology. Vol. 59, No. 5, pp. 542-545.<\/dc:identifier><dc:identifier>\n90006689<\/dc:identifier><dc:identifier>\n90009314<\/dc:identifier><dc:identifier>\n900100380<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/3430<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1111\/j.1365-2125.2005.02360.x<\/dc:relation>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1111\/j.1365-2125.2005.02360.x"],"year":2005,"topics":["Bioavailability","Gentamicin","Inhalation","Lungs","Nebulizer"],"subject":["Article","No full-text available in the repository"],"fullText":null}